返回
Passage Bio Inc（PASG）价格
PASG 股价走势图
PASG 收益
Passage Bio Inc
$12.87
-9.87%
$-1.41
收盘价：Jan 16, 16:00:00 GMT-5
$12.87
0%
$0
盘后：Jan 16, 20:00:00 GMT-5
关键数据
前收盘价
$14.28
开盘价
$14.32
当日区间
$12.5 - $14.8
52周范围
$5.12 - $20
交易量
40.3K
平均成交量
58.4K
每股收益（TTM）
-14.47
股息收益率
--
市值
$40.9M
什么是 PASG？
Passage Bio, Inc. operates as a genetic medicines company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 60 full-time employees. The company went IPO on 2020-02-28. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. The company has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.